Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • EvaluatePharma
      • Evaluate Omnium
      • Japan Drug Forecasts
      • European Drug Forecasts
      • Epi Analyzer
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Patent & Litigation

Thumbnail
January 15, 2021

The biotech resurrection continues

Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.

Thumbnail
January 04, 2021

The fate of Celgene security looks to follow that of Genzyme’s

Article image
Vantage logo
October 07, 2020

Thinking the unthinkable on Covid vaccine approvals

With the EU regulator already reviewing two coronavirus vaccines, could it beat the US FDA to the punch?

Article image
Vantage logo
September 03, 2020

Amarin forced to look to Europe as US patent hopes dashed

Article image
Vantage logo
August 20, 2020

Mylan only the first chink in Tecfidera’s armour

Article image
Vantage logo
August 12, 2020

Contingent value is back in vogue

This week another takeover included a CVR element, confirming a trend that has been gaining traction over the past year.

Article image
Vantage logo
August 06, 2020

Eliquis patent win adds a few billion to Bristol and Pfizer

Article image
Vantage logo
August 04, 2020

DBV confirms the inevitable

Article image
Vantage logo
July 27, 2020

Curevac muddies the Moderna/Arbutus waters further

The markets try to figure out who really benefits from last week’s patent decision over a key mRNA technology.

Article image
Vantage logo
July 24, 2020

The Covid-19 vaccine battle just got interesting

A patent claim against Arbutus is thrown out, threatening parts of Moderna’s mRNA technology – including its Covid-19 vaccine.

Article image
Vantage logo
July 22, 2020

Biogen gives investors something else to ponder

The company’s chief financial officer leaves on the eve of its second-quarter earnings report; should investors be worried?

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

December 10, 2020

Evaluate Vantage 2021 Preview

July 29, 2020

Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

View more...

Editor's Picks

Vantage logo
December 10, 2020

What the coming year might hold for biopharma

Vantage logo
December 11, 2020

Covid-19 vaccine developers remind the world that setbacks happen

Vantage logo
December 09, 2020

Astrazeneca’s vaccine looks increasingly like an also-ran

Vantage logo
November 09, 2020

Pfizer and Biontech snatch first Covid vaccine victory

Vantage logo
December 01, 2020

The promise and the perils of antigen testing

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2020 Evaluate Ltd.